Guidelines for antiretroviral therapy of human immunodeficiency virus (HIV)-infected subjects in the Czech Republic;Komplexní postup antiretrovirové léčby osob infikovaných virem lidské imunodeficience (HIV) v České republice

Klinicka Mikrobiologie a Infekcni Lekarstvi

Volumn 13, Issue 1, 2007, Pages 28-34

  Sedláček, Dalibor ^a   Stankova M ^b   Machala, L ^b   Rozsypal, H ^b   Snopkova S ^c   Dostal V ^d   Kolcakova J ^e   Dlouhy P ^f   Jerhotova J ^g  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^e AIDS Centrum   (Czech Republic)

^f Infek ní Odd lení Masarykova Nemocnice Ústí nad Labem   (Czech Republic)

^g AIDS Centrum   (Czech Republic)

Author keywords

Antiretroviral therapy; Antiviral agents; cART; HIV AIDS; Mother to child transmission; Prophylaxis

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMINOTRANSFERASE; AMPRENAVIR PHOSPHATE; AMPRENAVIR PHOSPHATE PLUS RITONAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; INDINAVIR PLUS RITONAVIR; INVIRASE 500; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDEX EC; ZIDOVUDINE;

ALOPECIA; ANEMIA; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CZECH REPUBLIC; ELECTROCARDIOGRAPHY; EUROPE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERPIGMENTATION; HYPERSENSITIVITY; IMMUNE DEFICIENCY; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LIPODYSTROPHY; MYALGIA; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PIGMENTATION; QUALITY OF LIFE; RASH; SIDE EFFECT; UNITED STATES; VERTICAL TRANSMISSION; VERTIGO; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CZECH REPUBLIC; HIV INFECTIONS; HUMANS;

EID: 34047215526     PISSN: 1211264X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rizzardi GP, Tambussi G, Bart PA. et al. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. AIDS 2000;14:2257-2263.
2. Palella Jr FJ, Chmiel JS, Moorman AC, Holmberg SD. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002;16:1617-1626.
3. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356: 1423-1430.
4. Donnerer J, Kronawetter M, Kapper A, Haas I, Kessler HH. Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, neviramine, indinavir, lopinavir, and nelfinavir. Pharmacology 2003;69(4):197-204.
5. Sedláček D, Stehlík P, Stožický F. Příspěvek ke kontrole adherence léčby antiretrovirovými přípravky. Klin Mikrobiol Inf Lék 2001;7(3):80-82.
6. Carpenter ChCJ, Kojic EM. HIV InSite Knowledge Base Chapter. Published January 2006, MD, Brown University. http://hivinsite.ucsf.edu/ InSite?page=kb-03-02-05
7. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med 2005;6(Suppl 2): 1-61.
8. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. http://www.aidsinfo.nih.gov. In: Services. DoHaH, ed.; 2005.
9. Yeni PG, Hammer SM, Hirsch MS. et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004;292:251-265.
10. Sterne J, May M, Costagliola D and ART Cohort Collaboration. Estimating the Optimum CD4 Threshold for Starting HAART in ART-naive HIV-infected Individuals. 13th CROI, Denver CO, 5.-8.únor 2006. Abstract 525.
11. Gisslen M, Alqvist-Rastad J, Albert J. et al. Antiretroviral treatment of HIV infection: Swedish recommendations 2005. Scand J Infect Dis 2006;38(2):86-103.
12. The EACS Executive Committee. European Guidelines for the Clinical Management and Treatment of HIV Infected Adults 2005. 10th EACS Conference, Dublin, 2005.
13. Hirsch MS, Brun-Vezinet F, Clotet B. et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37(1):113-128.
14. Leigh Brown AJ, Frost SD, Mathews WC. et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003;187:683-686.
15. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34: 1115-1121.
16. Kempf DJ, King MS, Bernstein B. et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189:51-60.
17. Phair JP, Mellors JW, Detels R, Margolick JB, Munoz A. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS 2002;16: 2455-2459.
18. Egger M, May M, Chene G. et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-129.
19. Shelburne SA, 3rd, Hamill RJ, Rodriguez-Barradas MC. et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002;81:213-227.